Elispot 2018

Ostatnie badanie wykazało ze test ELIspot NIE jest wiarygodny przy neuroboreliozie. 2018
---------------------------------------------------------------------------------
An ELISpot assay, measuring Borrelia burgdorferi B31-specific interferon-gamma secreting T-cells, cannot discriminate active Lyme neuroborreliosis from past Lyme borreliosis; a prospective study in the Netherlands

ABSTRACT

Two-tier serology testing is most frequently used for the diagnosis of Lyme borreliosis (LB); however, a positive result is no proof of active disease. To establish a diagnosis of active LB, better diagnostics are needed. Tests investigating the cellular immune system are available, but studies evaluating the utility of these tests on well-defined patient populations are lacking. Therefore, we investigated the utility of an enzyme-linked immunospot (ELISpot) assay to diagnose active Lyme neuroborreliosis. Peripheral blood mononuclear cells (PBMCs) of various study groups were stimulated by using Borrelia burgdorferi strain B31 and various recombinant antigens and subsequently, the number of Borrelia-specific interferon-gamma (IFN-γ) secreting T-cells was measured.

We included 33 active and 37 treated Lyme neuroborreliosis patients, 28 healthy individuals treated for an early manifestation of LB in the past and 145 untreated healthy individuals. The median number of B. burgdorferi B31-specific IFN-γ secreting T-cells/2.5x10⁵ PBMCs did not differ between active Lyme neuroborreliosis patients, treated Lyme neuroborreliosis patients and treated healthy individuals (6.0, interquartile range (IQR): 0.5 - 14.0; 4.5, IQR: 2.0 - 18.6; 7.4, IQR: 2.3 - 14.9; respectively) (p 1.000); however, the median number of B. burgdorferi B31-specific IFN-γ secreting T-cells/2.5x10⁵ PBMCs among untreated healthy individuals was lower (2.0, IQR: 0.5 - 3.9) (p ≤0.016).

We conclude that the Borrelia ELISpot, measuring the number of B. burgdorferi B31-specific INF-γ secreting T-cells/2.5x10⁵ PBMCs, correlates with exposure to the Borrelia bacterium, but cannot be used for the diagnosis of active Lyme neuroborreliosis.

http://jcm.asm.org/content/early/2018/01/18/JCM.01695-17.abstract?sid=185e11ec-14ac-4545-b9eb-511f0d869861

---------------------------------------
https://lymevereniging.nl/2018/01/28/cellulaire-test-geen-meerwaarde-lymeziekte-zenuwstelsel/
---------------------------------------

 

Hiperosmia – nadwrażliwość węchowa a Borelioza.

Neurological involvement in Lyme disease has been reported to include meningitis, cranial neuropathy and radiculoneuritis. While it is known that in some cases of asceptic meningitis patients may develop hyperosmia, the association between hyperosmia and Lyme disease has not previously been studied.

------------------

DISCUSSION

This first systematic controlled study showed that Lyme disease is associated with hyperosmia. In the sample studied, there was a highly significant prevalence of hyperosmia in Lyme disease of 50%.

Known migraineurs were excluded from this study and so it is unlikely that migraine could account for our finding. Again, as none of the subjects included in the study had clinical signs of meningitis, it is unlikely that meningitis could account for the high prevalence of hyperosmia in the Lyme disease group, although a subclinical form of meningitis associated with Lyme borreliosis cannot be ruled out as of importance. Finally, it should be noted that none of the medication taken by any of the patients is known to be associated with hyperosmia.

This is the first study of hyperosmia in Lyme disease. The high prevalence of this olfactory disorder found in our study suggests the need for further studies of olfactory function in this disease. It would also be of interest to carry out longitudinal studies to evaluate the response of hyperosmia to antibiotic pharmacotherapy

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2014000800596&lng=en&nrm=iso&tlng=en

--------------------------

 

NEUROBORELIOZA :

Do objawów tych zaliczamy m.in.:

• zmęczenie (około 90% pacjentów),
• zaburzenia pamięci (około 80% pacjentów),
• światłowstręt (około 70% pacjentów), w tym nadwrażliwość na światło komputera, telewizora i inne źródła światła,
• nadwrażliwość na dźwięki połączona z oczopląsem, nudnościami, wymiotami i agresją (około 30% pacjentów)
• nadwrażliwość zmysłów dotyku, smaku i węchu (około 20% pacjentów),
• wysoka drażliwość,
• zaburzenia nastroju (około 80% pacjentów), którym często towarzyszą stany lekowe tj.: podwyższony poziomu lęku, napady paniki oraz zaburzenia obsesyjno-kompulsywne,
• zaburzenia snu (trudności w zasypianiu, liczne wybudzenia w nocy, nadmierna senność w ciągu dnia),
• dezorientacja przestrzenna (około 57% pacjentów).

https://www.medme.pl/choroby/neuroborelioza,246.html